Global RNAi Technologies

RNAi Technologies Comprehensive Study by Type (Micro RNA (miRNA), Small Interfering RNA (siRNA)), Application (Oncology, Ocular disorders, Respiratory disorders, Liver diseases) Players and Region - Global Market Outlook to 2027

RNAi Technologies Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is RNAi Technologies Market?

RNAi technology is the biological process of mRNA degradation induced by complementary sequences of double-stranded small interfering RNAs and suppression of target gene expression. This technology includes a method of producing highly potent and purified siRNAs directly from Escherichiacoli cells. It offers the promise of a reduced risk approach to insect pest control. Rising the application of RNAi in molecular diagnosis and its viability as a therapeutic technique drive the global market growth.

Highlights from RNAi Technologies Market Study
AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledDicerna Pharmaceuticals (United States), TransCode Therapeutics (United States), Inceptor Bio (United States), Kodikaz Therapeutic (United States), Spark Therapeutics (United States), Phio Pharmaceuticals (United States), Sirnaomics, Inc (United States), Alnylam Pharmaceuticals (United States), Sirion Biotech (Germany) and Silence Therapeutics (United Kingdom)


The companies operating in this industry are focusing on efficient growth, improvement of operational efficiency and productivity, achieving high print and digital standards, and focus on maintaining sustainable development. The players are focusing on securing a leading position in this industry. They are continuously looking for the opportunity to reinforce their competitive advantage.

Dicerna Pharmaceuticals (United States), TransCode Therapeutics (United States), Inceptor Bio (United States), Kodikaz Therapeutic (United States), Spark Therapeutics (United States), Phio Pharmaceuticals (United States), Sirnaomics, Inc (United States), Alnylam Pharmaceuticals (United States), Sirion Biotech (Germany) and Silence Therapeutics (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Nanode Therapeutics, Inc. (United States), Genevant Sciences (United States) and Arbutus Biopharma (Canada).

RNAi Technologies Market Segmentation:
ScopeSub-Segments
Application / End UserOncology, Ocular disorders, Respiratory disorders and Liver diseases
TypeMicro RNA (miRNA) and Small Interfering RNA (siRNA)


On the basis of geography, the market of RNAi Technologies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Introduction of Techniques for the Identification of Altered Cellular Molecules and Metabolites

Market Growth Drivers:
Increasing Public Concern over the Risk that many of These Chemicals pose to the Environment and to Human and Livestock Health and Rising Molecular Diagnostics Applications, Cancer, and Genetic and Metabolic Disorders

Challenges:
Application of RNAi Technologies is the Major Challenging Factor for the Players

Restraints:
Stringent Regulations on the RNAi Technologies

Opportunities:
Growing Numbers of Research Groups and Biotechnology Industries can create Opportunities for the Market

Key Target Audience
RNAi Technologies Providers, Regulatory Bodies, Potential Investors, New Entrants, Research and Development Institutes and Others

Market Leaders & Development Strategies
In November 2021, Novo Nordisk announced the acquisition of Dicerna Pharmaceuticals. It is a strategic addition to Novo Nordisk’s research technology platforms and helps the strategy by the application of a broad range of technology platforms use around all of Novo Nordisk’s therapeutic focus areas. The acquisition of Dicerna accelerates Novo Nordisk’s research within RNAi and expands the usage of RNAi technology.
On 19th May 2022, TransCode Therapeutics announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF.


Report Objectives / Segmentation Covered

By Type
  • Micro RNA (miRNA)
  • Small Interfering RNA (siRNA)
By Application
  • Oncology
  • Ocular disorders
  • Respiratory disorders
  • Liver diseases
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Public Concern over the Risk that many of These Chemicals pose to the Environment and to Human and Livestock Health
      • 3.2.2. Rising Molecular Diagnostics Applications, Cancer, and Genetic and Metabolic Disorders
    • 3.3. Market Challenges
      • 3.3.1. Application of RNAi Technologies is the Major Challenging Factor for the Players
    • 3.4. Market Trends
      • 3.4.1. Introduction of Techniques for the Identification of Altered Cellular Molecules and Metabolites
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global RNAi Technologies, by Type, Application and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global RNAi Technologies (Value)
      • 5.2.1. Global RNAi Technologies by: Type (Value)
        • 5.2.1.1. Micro RNA (miRNA)
        • 5.2.1.2. Small Interfering RNA (siRNA)
      • 5.2.2. Global RNAi Technologies by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Ocular disorders
        • 5.2.2.3. Respiratory disorders
        • 5.2.2.4. Liver diseases
      • 5.2.3. Global RNAi Technologies Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Australia
          • 5.2.3.2.6. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global RNAi Technologies (Price)
      • 5.3.1. Global RNAi Technologies by: Type (Price)
  • 6. RNAi Technologies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Dicerna Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. TransCode Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Inceptor Bio (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Kodikaz Therapeutic (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Spark Therapeutics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Phio Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sirnaomics, Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Alnylam Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sirion Biotech (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Silence Therapeutics (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global RNAi Technologies Sale, by Type, Application and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global RNAi Technologies (Value)
      • 7.2.1. Global RNAi Technologies by: Type (Value)
        • 7.2.1.1. Micro RNA (miRNA)
        • 7.2.1.2. Small Interfering RNA (siRNA)
      • 7.2.2. Global RNAi Technologies by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Ocular disorders
        • 7.2.2.3. Respiratory disorders
        • 7.2.2.4. Liver diseases
      • 7.2.3. Global RNAi Technologies Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Australia
          • 7.2.3.2.6. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global RNAi Technologies (Price)
      • 7.3.1. Global RNAi Technologies by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. RNAi Technologies: by Type(USD Million)
  • Table 2. RNAi Technologies Micro RNA (miRNA) , by Region USD Million (2016-2021)
  • Table 3. RNAi Technologies Small Interfering RNA (siRNA) , by Region USD Million (2016-2021)
  • Table 4. RNAi Technologies: by Application(USD Million)
  • Table 5. RNAi Technologies Oncology , by Region USD Million (2016-2021)
  • Table 6. RNAi Technologies Ocular disorders , by Region USD Million (2016-2021)
  • Table 7. RNAi Technologies Respiratory disorders , by Region USD Million (2016-2021)
  • Table 8. RNAi Technologies Liver diseases , by Region USD Million (2016-2021)
  • Table 9. South America RNAi Technologies, by Country USD Million (2016-2021)
  • Table 10. South America RNAi Technologies, by Type USD Million (2016-2021)
  • Table 11. South America RNAi Technologies, by Application USD Million (2016-2021)
  • Table 12. Brazil RNAi Technologies, by Type USD Million (2016-2021)
  • Table 13. Brazil RNAi Technologies, by Application USD Million (2016-2021)
  • Table 14. Argentina RNAi Technologies, by Type USD Million (2016-2021)
  • Table 15. Argentina RNAi Technologies, by Application USD Million (2016-2021)
  • Table 16. Rest of South America RNAi Technologies, by Type USD Million (2016-2021)
  • Table 17. Rest of South America RNAi Technologies, by Application USD Million (2016-2021)
  • Table 18. Asia Pacific RNAi Technologies, by Country USD Million (2016-2021)
  • Table 19. Asia Pacific RNAi Technologies, by Type USD Million (2016-2021)
  • Table 20. Asia Pacific RNAi Technologies, by Application USD Million (2016-2021)
  • Table 21. China RNAi Technologies, by Type USD Million (2016-2021)
  • Table 22. China RNAi Technologies, by Application USD Million (2016-2021)
  • Table 23. Japan RNAi Technologies, by Type USD Million (2016-2021)
  • Table 24. Japan RNAi Technologies, by Application USD Million (2016-2021)
  • Table 25. India RNAi Technologies, by Type USD Million (2016-2021)
  • Table 26. India RNAi Technologies, by Application USD Million (2016-2021)
  • Table 27. South Korea RNAi Technologies, by Type USD Million (2016-2021)
  • Table 28. South Korea RNAi Technologies, by Application USD Million (2016-2021)
  • Table 29. Australia RNAi Technologies, by Type USD Million (2016-2021)
  • Table 30. Australia RNAi Technologies, by Application USD Million (2016-2021)
  • Table 31. Rest of Asia-Pacific RNAi Technologies, by Type USD Million (2016-2021)
  • Table 32. Rest of Asia-Pacific RNAi Technologies, by Application USD Million (2016-2021)
  • Table 33. Europe RNAi Technologies, by Country USD Million (2016-2021)
  • Table 34. Europe RNAi Technologies, by Type USD Million (2016-2021)
  • Table 35. Europe RNAi Technologies, by Application USD Million (2016-2021)
  • Table 36. Germany RNAi Technologies, by Type USD Million (2016-2021)
  • Table 37. Germany RNAi Technologies, by Application USD Million (2016-2021)
  • Table 38. France RNAi Technologies, by Type USD Million (2016-2021)
  • Table 39. France RNAi Technologies, by Application USD Million (2016-2021)
  • Table 40. Italy RNAi Technologies, by Type USD Million (2016-2021)
  • Table 41. Italy RNAi Technologies, by Application USD Million (2016-2021)
  • Table 42. United Kingdom RNAi Technologies, by Type USD Million (2016-2021)
  • Table 43. United Kingdom RNAi Technologies, by Application USD Million (2016-2021)
  • Table 44. Netherlands RNAi Technologies, by Type USD Million (2016-2021)
  • Table 45. Netherlands RNAi Technologies, by Application USD Million (2016-2021)
  • Table 46. Rest of Europe RNAi Technologies, by Type USD Million (2016-2021)
  • Table 47. Rest of Europe RNAi Technologies, by Application USD Million (2016-2021)
  • Table 48. MEA RNAi Technologies, by Country USD Million (2016-2021)
  • Table 49. MEA RNAi Technologies, by Type USD Million (2016-2021)
  • Table 50. MEA RNAi Technologies, by Application USD Million (2016-2021)
  • Table 51. Middle East RNAi Technologies, by Type USD Million (2016-2021)
  • Table 52. Middle East RNAi Technologies, by Application USD Million (2016-2021)
  • Table 53. Africa RNAi Technologies, by Type USD Million (2016-2021)
  • Table 54. Africa RNAi Technologies, by Application USD Million (2016-2021)
  • Table 55. North America RNAi Technologies, by Country USD Million (2016-2021)
  • Table 56. North America RNAi Technologies, by Type USD Million (2016-2021)
  • Table 57. North America RNAi Technologies, by Application USD Million (2016-2021)
  • Table 58. United States RNAi Technologies, by Type USD Million (2016-2021)
  • Table 59. United States RNAi Technologies, by Application USD Million (2016-2021)
  • Table 60. Canada RNAi Technologies, by Type USD Million (2016-2021)
  • Table 61. Canada RNAi Technologies, by Application USD Million (2016-2021)
  • Table 62. Mexico RNAi Technologies, by Type USD Million (2016-2021)
  • Table 63. Mexico RNAi Technologies, by Application USD Million (2016-2021)
  • Table 64. RNAi Technologies: by Type(USD/Units)
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. RNAi Technologies: by Type(USD Million)
  • Table 76. RNAi Technologies Micro RNA (miRNA) , by Region USD Million (2022-2027)
  • Table 77. RNAi Technologies Small Interfering RNA (siRNA) , by Region USD Million (2022-2027)
  • Table 78. RNAi Technologies: by Application(USD Million)
  • Table 79. RNAi Technologies Oncology , by Region USD Million (2022-2027)
  • Table 80. RNAi Technologies Ocular disorders , by Region USD Million (2022-2027)
  • Table 81. RNAi Technologies Respiratory disorders , by Region USD Million (2022-2027)
  • Table 82. RNAi Technologies Liver diseases , by Region USD Million (2022-2027)
  • Table 83. South America RNAi Technologies, by Country USD Million (2022-2027)
  • Table 84. South America RNAi Technologies, by Type USD Million (2022-2027)
  • Table 85. South America RNAi Technologies, by Application USD Million (2022-2027)
  • Table 86. Brazil RNAi Technologies, by Type USD Million (2022-2027)
  • Table 87. Brazil RNAi Technologies, by Application USD Million (2022-2027)
  • Table 88. Argentina RNAi Technologies, by Type USD Million (2022-2027)
  • Table 89. Argentina RNAi Technologies, by Application USD Million (2022-2027)
  • Table 90. Rest of South America RNAi Technologies, by Type USD Million (2022-2027)
  • Table 91. Rest of South America RNAi Technologies, by Application USD Million (2022-2027)
  • Table 92. Asia Pacific RNAi Technologies, by Country USD Million (2022-2027)
  • Table 93. Asia Pacific RNAi Technologies, by Type USD Million (2022-2027)
  • Table 94. Asia Pacific RNAi Technologies, by Application USD Million (2022-2027)
  • Table 95. China RNAi Technologies, by Type USD Million (2022-2027)
  • Table 96. China RNAi Technologies, by Application USD Million (2022-2027)
  • Table 97. Japan RNAi Technologies, by Type USD Million (2022-2027)
  • Table 98. Japan RNAi Technologies, by Application USD Million (2022-2027)
  • Table 99. India RNAi Technologies, by Type USD Million (2022-2027)
  • Table 100. India RNAi Technologies, by Application USD Million (2022-2027)
  • Table 101. South Korea RNAi Technologies, by Type USD Million (2022-2027)
  • Table 102. South Korea RNAi Technologies, by Application USD Million (2022-2027)
  • Table 103. Australia RNAi Technologies, by Type USD Million (2022-2027)
  • Table 104. Australia RNAi Technologies, by Application USD Million (2022-2027)
  • Table 105. Rest of Asia-Pacific RNAi Technologies, by Type USD Million (2022-2027)
  • Table 106. Rest of Asia-Pacific RNAi Technologies, by Application USD Million (2022-2027)
  • Table 107. Europe RNAi Technologies, by Country USD Million (2022-2027)
  • Table 108. Europe RNAi Technologies, by Type USD Million (2022-2027)
  • Table 109. Europe RNAi Technologies, by Application USD Million (2022-2027)
  • Table 110. Germany RNAi Technologies, by Type USD Million (2022-2027)
  • Table 111. Germany RNAi Technologies, by Application USD Million (2022-2027)
  • Table 112. France RNAi Technologies, by Type USD Million (2022-2027)
  • Table 113. France RNAi Technologies, by Application USD Million (2022-2027)
  • Table 114. Italy RNAi Technologies, by Type USD Million (2022-2027)
  • Table 115. Italy RNAi Technologies, by Application USD Million (2022-2027)
  • Table 116. United Kingdom RNAi Technologies, by Type USD Million (2022-2027)
  • Table 117. United Kingdom RNAi Technologies, by Application USD Million (2022-2027)
  • Table 118. Netherlands RNAi Technologies, by Type USD Million (2022-2027)
  • Table 119. Netherlands RNAi Technologies, by Application USD Million (2022-2027)
  • Table 120. Rest of Europe RNAi Technologies, by Type USD Million (2022-2027)
  • Table 121. Rest of Europe RNAi Technologies, by Application USD Million (2022-2027)
  • Table 122. MEA RNAi Technologies, by Country USD Million (2022-2027)
  • Table 123. MEA RNAi Technologies, by Type USD Million (2022-2027)
  • Table 124. MEA RNAi Technologies, by Application USD Million (2022-2027)
  • Table 125. Middle East RNAi Technologies, by Type USD Million (2022-2027)
  • Table 126. Middle East RNAi Technologies, by Application USD Million (2022-2027)
  • Table 127. Africa RNAi Technologies, by Type USD Million (2022-2027)
  • Table 128. Africa RNAi Technologies, by Application USD Million (2022-2027)
  • Table 129. North America RNAi Technologies, by Country USD Million (2022-2027)
  • Table 130. North America RNAi Technologies, by Type USD Million (2022-2027)
  • Table 131. North America RNAi Technologies, by Application USD Million (2022-2027)
  • Table 132. United States RNAi Technologies, by Type USD Million (2022-2027)
  • Table 133. United States RNAi Technologies, by Application USD Million (2022-2027)
  • Table 134. Canada RNAi Technologies, by Type USD Million (2022-2027)
  • Table 135. Canada RNAi Technologies, by Application USD Million (2022-2027)
  • Table 136. Mexico RNAi Technologies, by Type USD Million (2022-2027)
  • Table 137. Mexico RNAi Technologies, by Application USD Million (2022-2027)
  • Table 138. RNAi Technologies: by Type(USD/Units)
  • Table 139. Research Programs/Design for This Report
  • Table 140. Key Data Information from Secondary Sources
  • Table 141. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global RNAi Technologies: by Type USD Million (2016-2021)
  • Figure 5. Global RNAi Technologies: by Application USD Million (2016-2021)
  • Figure 6. South America RNAi Technologies Share (%), by Country
  • Figure 7. Asia Pacific RNAi Technologies Share (%), by Country
  • Figure 8. Europe RNAi Technologies Share (%), by Country
  • Figure 9. MEA RNAi Technologies Share (%), by Country
  • Figure 10. North America RNAi Technologies Share (%), by Country
  • Figure 11. Global RNAi Technologies: by Type USD/Units (2016-2021)
  • Figure 12. Global RNAi Technologies share by Players 2021 (%)
  • Figure 13. Global RNAi Technologies share by Players (Top 3) 2021(%)
  • Figure 14. Global RNAi Technologies share by Players (Top 5) 2021(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Dicerna Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Dicerna Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 18. TransCode Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 19. TransCode Therapeutics (United States) Revenue: by Geography 2021
  • Figure 20. Inceptor Bio (United States) Revenue, Net Income and Gross profit
  • Figure 21. Inceptor Bio (United States) Revenue: by Geography 2021
  • Figure 22. Kodikaz Therapeutic (United States) Revenue, Net Income and Gross profit
  • Figure 23. Kodikaz Therapeutic (United States) Revenue: by Geography 2021
  • Figure 24. Spark Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 25. Spark Therapeutics (United States) Revenue: by Geography 2021
  • Figure 26. Phio Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 27. Phio Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 28. Sirnaomics, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 29. Sirnaomics, Inc (United States) Revenue: by Geography 2021
  • Figure 30. Alnylam Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Alnylam Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 32. Sirion Biotech (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Sirion Biotech (Germany) Revenue: by Geography 2021
  • Figure 34. Silence Therapeutics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Silence Therapeutics (United Kingdom) Revenue: by Geography 2021
  • Figure 36. Global RNAi Technologies: by Type USD Million (2022-2027)
  • Figure 37. Global RNAi Technologies: by Application USD Million (2022-2027)
  • Figure 38. South America RNAi Technologies Share (%), by Country
  • Figure 39. Asia Pacific RNAi Technologies Share (%), by Country
  • Figure 40. Europe RNAi Technologies Share (%), by Country
  • Figure 41. MEA RNAi Technologies Share (%), by Country
  • Figure 42. North America RNAi Technologies Share (%), by Country
  • Figure 43. Global RNAi Technologies: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Dicerna Pharmaceuticals (United States)
  • TransCode Therapeutics (United States)
  • Inceptor Bio (United States)
  • Kodikaz Therapeutic (United States)
  • Spark Therapeutics (United States)
  • Phio Pharmaceuticals (United States)
  • Sirnaomics, Inc (United States)
  • Alnylam Pharmaceuticals (United States)
  • Sirion Biotech (Germany)
  • Silence Therapeutics (United Kingdom)
Additional players considered in the study are as follows:
Nanode Therapeutics, Inc. (United States) , Genevant Sciences (United States) , Arbutus Biopharma (Canada)
Select User Access Type

Key Highlights of Report


Jul 2022 233 Pages 70 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global RNAi Technologies Quantitative research analysis
Global RNAi Technologies Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Public Concern over the Risk that many of These Chemicals pose to the Environment and to Human and Livestock Health " is seen as one of major growth factors of RNAi Technologies Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The RNAi Technologies market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global RNAi Technologies Report?

Have a Query? Click Here

Other Related Reports

Vegetarian Capsules Comprehensive Study by Type (Pullulan, Starch, HPMC), Application (Pharmaceutical, Health Supplements, Others), Distribution Channel (Online, Offline) Players and Region - Global ...
$ 3500
AI In Medical Imaging Comprehensive Study by Application (Digital Pathology, Orthopedics, Cardiology, Urology, Gastrology, Neurology, Others), AI Technology (Computer Vision, Deep Learning, Others), ...
$ 3750
Medical Coding Service Comprehensive Study by Type (International Classification of Diseases, Healthcare Common Procedure Code System), Application (Hospitals, Clinics, Nursing Home, Others), Compone...
$ 3350
Pharmacy Management Software Comprehensive Study by Deployment Mode (Cloud-based, On-premise), Component (Software, Service {Mail-order Pharmacy Services, Non-mail Pharmacy Services}), End Use (Hos...
$ 3350
Healthcare Antimicrobial Plastics Comprehensive Study by Type (Commodity Plastic, Engineering Plastic, High Performance Plastic), Application (Hospital, Pharmacy, Medical Research), Additive (Inorgan...
$ 3500
Monogenetic Disorders Testing Comprehensive Study by Type (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive & Pre-Symptomatic Testing, Prenatal Testing, Others), Application (Hospi...
$ 3750